4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Blepharitis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 31 ongoing clinical trials involving Blepharitis
Of the 31 trials,15 trials are in Phase II
Furthermore, 6 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Blepharitis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Blepharitis, anophthalmologycondition.The largest number of ongoing clinical trial forBlepharitisis conducted in Asia-Pacific. North Americaand Europe are among some of the other prominent regionsinvolved in Blepharitis-related drug trials.

Tarsus Pharmaceuticals Inc: The leading ongoing Blepharitis related clinical trialsponsor

Tarsus Pharmaceuticals Incis the leading sponsor for Blepharitis-related ongoing clinical trials.

Medical University of Vienna, Peking University Third Hospital, Itoh Clinic, and Beijing Tongren Hospitalare a few other notable clinical trial sponsors involved inBlepharitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Blepharitis

Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone) is a glucocorticoid, anti-inflammatory agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as tablets for oral administration, lyophilized powder for solution, Methylprednisolone is marketed for the treatment of Blepharitis and several other indications including Multiple Sclerosis, Arthritis, Osteoarthritis, Asthma, Allergic Rhinitis, Lupus Nephritis, Hypoglycemia, Alopecia, Seborrhea, Liver Cirrhosis, Proteinuria, Myasthenia Gravis, Sarcoidosis, Fever, Uveitis, Hematopoietic Stem Cell Transplantation, Pneumonia, Juvenile Rheumatoid Arthritis, Hemorrhagic Shock, Vasculitis, Enteritis, Encephalitis, Addison's Disease (Primary or Chronic Adrenal Insufficiency), Serum Sickness, Anaphylaxis, Polymyositis, Bacterial (Pyogenic) Meningitis, Tuberculous Meningitis, and Gouty Arthritis (Gout). Methylprednisolone was first approved in 1957 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including Pfizer Inc.

Levofloxacin (Cravit, Levaquin, Tavanic, Quixin, Oftaquix) is an anti-microbial agent belongs to fluoroquinolones. It functions via DNA Gyrase (EC 5.99.1.3) Inhibitor; DNA Topoisomerase IV (EC 5.99.1.3) Inhibitor mechanism of action. It is formulated as film-coated tablets for oral route of administration, injection for intravenous route of administration and solution for ophthalmic administration. Levofloxacin is marketed for the treatment of Blepharitis and several other indications includingUrinary Tract Infections, Bacterial Conjunctivitis, Cholangitis, Cholecystitis, Enteritis, Bacterial Pneumonia, Cholera, Abscess, Bacteremia, Cellulitis, Upper Respiratory Tract Infections, Acute Laryngitis, Chronic Bronchitis, Lower Respiratory Tract Infections, Complicated Skin and Skin Structure Infections (cSSSI), and Community Acquired Pneumonia. Levofloxacinwas first approved in 1996 and is marketed globally including the US, the UK, France, Germany, China, and Japan by Daiichi Sankyo Co Ltd, Janssen Pharmaceuticals Inc, and Sanofi.